CN1781536A - Chinese medicine compound preparation for treating hyperthyoidism - Google Patents
Chinese medicine compound preparation for treating hyperthyoidism Download PDFInfo
- Publication number
- CN1781536A CN1781536A CN 200510096052 CN200510096052A CN1781536A CN 1781536 A CN1781536 A CN 1781536A CN 200510096052 CN200510096052 CN 200510096052 CN 200510096052 A CN200510096052 A CN 200510096052A CN 1781536 A CN1781536 A CN 1781536A
- Authority
- CN
- China
- Prior art keywords
- thyroid
- chinese medicine
- hyperthyroidism
- treating
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
The present invention relates to a kind of Chinese medicine preparation, named Jiazhuangling, for treating hyperthyroidism, thyroid tumor, thyroid cyst and endemic goiter. The Chinese medicine preparation has obvious curative effect, short treating period and less recurrence.
Description
Technical field:
The present invention relates to a kind ofly can treat hyperthyroidism, Chinese medicine preparation strumous, belonging to plant is raw-material field of medicine preparations.
Background technology:
The ill ratio of hyperthyroidism (hyperthyroidism) and goiter sickness rate height, especially teenager in the crowd is higher.The treatment hyperthyroidism has the three major types therapy usually---oral antithyroid drug, radioiodine and operative treatment.Generally speaking, the doctor of the U.S. is than the preference radioiodine therapy, and the doctor of Europe and Japan is the preference antithyroid drug then.
One, Drug therapy utilizes Thiourea medicine (propylthiouracil) and imidazoles (thiamazole) to suppress the synthetic of thyroxin.Patient Ke Jia beta-blocker propranolol or metoprolol that the treatment initial stage is fast to heart rate; Can be with symptomatic treatments such as tranquilizer are stable to the patient of insomnia, anxiety.Drug therapy must check that T3, T4, TSH, liver function and routine blood test are to adjust the dosage of antithyroid drug in every month.Excessive as drug dose, can cause thyroid function low; Then hyperthyroidism symptom of underdosage can not be controlled, and hyperthyroidism symptom long-term control is bad, can cause hyperthyroid heart disease, cardiac dilatation, atrial fibrillation and heart failure etc., so Drug therapy more complicated.Drug therapy need be taken medicine for a long time, the course of treatment at least 1~1.5 year, and cure rate is less than 40%, about 50~60% patient recurrence after the drug withdrawal.In addition, the medicine common adverse effect is more, as granulocytopenia, liver function injury and erythra etc. occur, 1/3-1/4 patient's drug withdrawal owing to the untoward reaction that can not tolerate medicine.Some serious side effects such as obstructive jaundice and toxic hepatitis etc.
Two, radioiodine therapy utilizes thyroid to have to concentrate the ability of iodine and iodine can discharge Beta-ray effect and makes that follicular epithelial cell destroys, atrophy, and secretion reduces, and reaches therapeutic purposes.Usually patient only need take primary emission iodine, if poor effect then can be appended once after half a year or 1 year again.With regard to the radioiodine therapy hyperthyroidism, the thyroid volume in treatment back can dwindle gradually, hypothyroidism (hypothyroidism) occurs, even the part patient can permanent hypothyroidism too much occur because of thyroid destroys.After external data shows the radioiodine therapy hyperthyroidism, the incidence rate of hypothyroidism can be up to 50% in 1 year, and permanent hypothyroidism incidence rate increases progressively with the ratio of annual 1%-3%, does not still have the method for preventing its generation at present, can only give thyroxin lifelong replacement therapy.For individual patient, also can bring out thyroid storm or increase the weight of infiltrative exophthalmos.Following situation is not suitable for this treatment: 1. trimester of pregnancy, age of sucking; 2. the age is person below 20 years old; 3. peripheral blood leukocyte<3000/ cubic millimeter or neutral<1500/ cubic millimeter; 4. the severe heart, liver, renal failure; 5. severe infiltrative exophthalmos; 6. hyperthyroidism crisis.
Three, relapse rate is low after the operative treatment subtotal thyroidectomy, but operation is destructive irreversible treatment, and can cause some complication, answers careful selection.For preceding two classes treatment, the danger of operative treatment is big, the expense height, and side effect is many.Cut and lacked the postoperative hyperthyroidism and recur easily, cut many and hypothyroidism occurred.Main complication is that parathyroid injury causes hypoparathyroidism and recurrent nerve injury, and incidence rate is 1%-2%.Postoperative hyperthyroidism relapse rate is about 10%.The person has to be not suitable for the operative treatment: 1. infiltrative exophthalmos person; 2. severe cardiac, liver, kidney, lung complication, whole body situation difference can not tolerate surgery person; 3. pregnant early stage (preceding 3 months) and late period (back 3 months); 4. light disease patient estimates that Drug therapy can alleviation person.
Hyperthyroidism is still anosis because of treatment.There are tens million of patients in China, strictly says, the effect of three kinds of conventional treatments is all undesirable.
Motherland's medical science is to the understanding of thyroid disease: thyroid disease belongs to wart disease in motherland's medical science; Titles such as hemangioma of the neck, goiter due to disorder of QI, toxic goiter, stony goiter, labor wart, native wart, melancholy wart and muscle wart are arranged.Wherein with hyperthyroidism nearer toxic goiter, goiter due to disorder of QI, melancholy wart arranged.Still had palpitation is seized with terror swollen etc. in addition.
The cause of disease: 1. exopathogenic factor: water and soil is inappropriate, exopathogen invasion and attack, the evil poison of six climate exopathogens, invade body, interior impairment of ZANG FU-organs etc.
2. endogenous cause of ill: the natural endowment deficiency, the kidney being the origin of congenital constitution, and deficiency of kidney yin can cause excessive rising of liver-YANG; Insufficiency of kidney-YANG, failure of qi transforming fluid is for expectorant is drink.Day after tomorrow conditioning mistake degree is as feelings will internal injury eating and drinking without temperance etc.Feelings will internal injury mostly is the living hot perverse and unreasonable manner criminal of depressed rage impairing the liver obstruction of QI fire-transformation spleen and causes humidogene expectorant.
Pathogenesis: under multiple paathogenic factor effect, the five internal organs all can be got involved, and are the most obvious with Liver and kidney.Feelings will internal injury causes qi depression to blood stasis, the phlegm-damp cohesion.Stagnation of liver-QI is not relaxed, and gas is rate blood not, causes the expectorant blood coagulation stasis of blood.Stagnated QI transforming into fire must not be led off, the moon of must feeling frustrated.Basic pathogenesis is a basis with the deficiency of YIN or yang deficiency, and the gas fire-phlegm stasis of blood wherein is again basic factor with the dry phlegm-syndrome for mark.
Therapeutic Principle: the timid expectorant of heat clearing away, soothing liver-QI for relieving depression, vital energy regualting and blood circulation-promoting, clearing away phlegm softening the hard mass, timid expectorant eliminating stagnation.
Summary of the invention:
The objective of the invention is to remedy the deficiencies in the prior art part, and provide a kind of evident in efficacy, the desirable medicine of treatment hyperthyroidism, thyroid tumor, thyroid cyst and the endemic goiter that has no side effect.
The specific embodiment:
The present invention realizes in the following way:
The Chinese medicine of following component is the effective ingredient of compound Chinese medicinal preparation of the present invention (spirit of first shape)
Sargassum 10%~30% Thallus Laminariae (Thallus Eckloniae) 10%~30% Spica Prunellae 10%~30%
Semen Sinapis Albae 10%~30% Rhizoma Dioscoreae Bulbiferae 10%~30% Bulbus Fritillariae Thunbergii 10%~30%
Radix Salviae Miltiorrhizae 10%~30% Herba Taraxaci 10%~30%
The present invention can also realize (optimal components ratio scope) by following measure:
Sargassum 10%~20% Thallus Laminariae (Thallus Eckloniae) 10%~20% Spica Prunellae 10%~20%
Semen Sinapis Albae 15%~25% Rhizoma Dioscoreae Bulbiferae 15%~25% Bulbus Fritillariae Thunbergii 10%~20%
Radix Salviae Miltiorrhizae 15%~25% Herba Taraxaci 15%~25%
The Chinese medicine preparation that the Chinese medicine of above-mentioned component makes with conventional production method can be powder, capsule, close ball, electuary, oral liquid and injection etc.
This Chinese medicine preparation prescription is inventor's secret recipe handed down in the family.Wherein: the timid expectorant softening the hard mass of Sargassum, Thallus Laminariae (Thallus Eckloniae), Rhizoma Dioscoreae Bulbiferae and Semen Sinapis Albae, eliminating stagnation disappear wart for monarch; Spica Prunellae regulate the flow of vital energy resolving depression, relieving inflammation or internal heat is minister; Radix Salviae Miltiorrhizae is invigorated blood circulation timid expectorant for helping; Herba Taraxaci heat-clearing and toxic substances removing, dispersing swelling and dissipating binds are for making.All medicines are played the merit of the resolving depression of regulating the flow of vital energy, clearing away phlegm softening the hard mass, blood circulation promoting and dispersing pathogen accumulation, heat-clearing and toxic substances removing altogether.
The present invention and prior art relatively have following advantage:
1, Chinese medicine preparation first shape of the present invention spirit electuary treatment thyroid disease effect significantly, short treating period, relapse rate be low, remove the trouble of taking medicine for a long time from.To various hyperthyroidism, can in March, cure.To thyroid tumor, thyroid cyst and endemic goiter etc., can in February, cure (except the hypothyroidism patient).
Clinical observation 218 routine patients (comprising hyperthyroidism, thyroid tumor, thyroid cyst and endemic goiter), male 49 people wherein, women 169 people, minimum 17 years old of age, maximum 52 years old, 33.8 years old mean age.The course of disease is the shortest 5 months, and is the longest 20 years.Take the each 40g of first shape spirit electuary, every day twice, 28 days the shortest courses of treatment, 4 months the longest courses of treatment.Total effective rate 98.6%, healing rate 90.8%, relapse rate only was 1.8% in invalid 1.4%, 5 year.
2, Chinese medicine preparation first shape spirit of the present invention is a Chinese patent medicine, and no chemical constituent and additive have no side effect to human body.Margin of safety experiment shows, takes the first shape spirit of 200 times of concentration of adult's consumption to rat, do not see intoxicating phenomenon.Take the first shape spirit of 200 times of concentration of adult's consumption continuous February for rabbit and Canis familiaris L., do not see the cumulative toxicity reaction.
3, Chinese medicine preparation first shape spirit electuary of the present invention is treated the consumption and the untoward reaction that can obviously reduce antithyroid drug when various hyperthyroidism, thyroid tumor, thyroid cyst and endemic goiter merge the antithyroid drug application.
Claims (2)
1, a kind of compound Chinese medicinal preparation first shape spirit electuary that can treat hyperthyroidism, thyroid tumor, thyroid cyst and endemic goiter is characterized in that containing the middle pharmaceutically active ingredient of following combination:
Sargassum 10%~30% Thallus Laminariae (Thallus Eckloniae) 10%~30% Spica Prunellae 10%~30%
Semen Sinapis Albae 10%~30% Rhizoma Dioscoreae Bulbiferae 10%~30% Bulbus Fritillariae Thunbergii 10%~30%
Radix Salviae Miltiorrhizae 10%~30% Herba Taraxaci 10%~30%.
2, according to claim 1 described among medicament mixture, it is characterized in that containing the middle pharmaceutically active ingredient effect better (optimal components ratio scope) of following component:
Sargassum 10%~20% Thallus Laminariae (Thallus Eckloniae) 10%~20% Spica Prunellae 10%~20%
Semen Sinapis Albae 15%~25% Rhizoma Dioscoreae Bulbiferae 15%~25% Bulbus Fritillariae Thunbergii 10%~20%
Radix Salviae Miltiorrhizae 15%~25% Herba Taraxaci 15%~25%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100960524A CN100374139C (en) | 2005-09-22 | 2005-09-22 | Chinese medicine compound preparation for treating hyperthyoidism |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005100960524A CN100374139C (en) | 2005-09-22 | 2005-09-22 | Chinese medicine compound preparation for treating hyperthyoidism |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1781536A true CN1781536A (en) | 2006-06-07 |
CN100374139C CN100374139C (en) | 2008-03-12 |
Family
ID=36772408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005100960524A Expired - Fee Related CN100374139C (en) | 2005-09-22 | 2005-09-22 | Chinese medicine compound preparation for treating hyperthyoidism |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN100374139C (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432333A (en) * | 2013-08-17 | 2013-12-11 | 广州市云桥生物科技有限公司 | Composition consisting of effective traditional Chinese medicine parts and used for treating hypothyroidism |
CN103432476A (en) * | 2013-08-17 | 2013-12-11 | 广州市云桥生物科技有限公司 | Composition consisting of effective traditional Chinese medicine parts and used for treating hyperthyroidism |
CN104042997A (en) * | 2014-06-22 | 2014-09-17 | 上海浦东高星生物技术研究所 | Hyperthyroidism treating pills |
CN105287901A (en) * | 2015-11-27 | 2016-02-03 | 黄德禄 | Traditional Chinese medicine pill for treating thyrophyma |
CN106075008A (en) * | 2016-06-15 | 2016-11-09 | 山东仙河药业有限公司 | A kind of Spica Prunellae granule and preparation method thereof |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104547831A (en) * | 2015-02-09 | 2015-04-29 | 王秋霞 | Qi-supplementing yin-nourishing medicinal liquor for patients suffering from hyperthyroidism and preparation method of qi-supplementing yin-nourishing medicinal liquor |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1053369C (en) * | 1996-02-07 | 2000-06-14 | 程先敏 | Medicine for treating thyreoidism |
CN1085099C (en) * | 1999-10-26 | 2002-05-22 | 马俊杰 | Medicine for treating thyroid enlargement and thyroidism |
-
2005
- 2005-09-22 CN CNB2005100960524A patent/CN100374139C/en not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103432333A (en) * | 2013-08-17 | 2013-12-11 | 广州市云桥生物科技有限公司 | Composition consisting of effective traditional Chinese medicine parts and used for treating hypothyroidism |
CN103432476A (en) * | 2013-08-17 | 2013-12-11 | 广州市云桥生物科技有限公司 | Composition consisting of effective traditional Chinese medicine parts and used for treating hyperthyroidism |
CN103432476B (en) * | 2013-08-17 | 2015-04-15 | 张群 | Composition consisting of effective traditional Chinese medicine parts and used for treating hyperthyroidism |
CN103432333B (en) * | 2013-08-17 | 2015-04-15 | 张群 | Composition consisting of effective traditional Chinese medicine parts and used for treating hypothyroidism |
CN104042997A (en) * | 2014-06-22 | 2014-09-17 | 上海浦东高星生物技术研究所 | Hyperthyroidism treating pills |
CN105287901A (en) * | 2015-11-27 | 2016-02-03 | 黄德禄 | Traditional Chinese medicine pill for treating thyrophyma |
CN106075008A (en) * | 2016-06-15 | 2016-11-09 | 山东仙河药业有限公司 | A kind of Spica Prunellae granule and preparation method thereof |
CN106075008B (en) * | 2016-06-15 | 2020-02-07 | 山东仙河药业有限公司 | Selfheal granules and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN100374139C (en) | 2008-03-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100374139C (en) | Chinese medicine compound preparation for treating hyperthyoidism | |
CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
CN101843694B (en) | Chinese medicament for treating chronic hepatitis | |
CN1150925C (en) | Chinese Patent medicine for curing deafness | |
CN101032619A (en) | Liquid medicine to be taken orally for curing primary hypertension and the preparing method | |
CN1879783A (en) | A medicine for treating diabetes | |
CN1698736A (en) | Externally applied medicine for treating mammary glands hyperplasia and preventing mammary cancer | |
CN106344772A (en) | traditional Chinese medicine composition for treating rhinitis, external preparation and preparation method thereof | |
CN1682787A (en) | Ruankang good for breast | |
CN102198182A (en) | Medicament for treatment of interstitial pneumonia | |
CN101843704B (en) | Chinese medicament for treating chronic hepatitis | |
CN101336990B (en) | Medicine for treating cholecystitis | |
CN101284059A (en) | Chinese medicinal materials preparation for reinforcing the spleen and kidney and curing the chronic nephritis | |
CN101912566B (en) | Traditional Chinese medicine for treating palpitation | |
CN103656032A (en) | Chinese patent medicine for treating mammitis and mastocarcinoma and preparation method thereof | |
CN1274360C (en) | Antiphlogistic and antitussive medicine powder | |
CN103028088B (en) | Traditional Chinese medicine composition for treating coronary heart disease and angina | |
CN101066343A (en) | Externally applied Chinese medicine for treating tonisillitis and lymphnoditis and its prepn process | |
CN101983681A (en) | Medicament for treating abnormal leucorrhea | |
CN101757223B (en) | Externally-applied traditional Chinese medicine for treating psoriasis | |
CN101249250A (en) | Medicinal liquor preparations for curing stagnation and blood stasis chest stuffiness and pain | |
CN105687659A (en) | Medicine patch for treating cesarean-postoperative abdominal incision sclerosis | |
CN104623549A (en) | Traditional Chinese medicine preparation for treating costal chondritis | |
CN105168613A (en) | Traditional Chinese medicine preparation for treating leukemia at emergency stage | |
Wu et al. | Analysis of The Rule of Traditional Chinese Medicine for Treating Herpes Zoster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C57 | Notification of unclear or unknown address | ||
DD01 | Delivery of document by public notice |
Addressee: Liu Wenlong Document name: Correction notice |
|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C17 | Cessation of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20080312 Termination date: 20091022 |